Parkinson's disease: Prospects for improved drug therapy

Trends in Pharmacological Sciences

Volumn 18, Issue 5, 1997, Pages 156-163

  Hagan, Jim J ^a   Middlemiss, Derek N ^a   Sharpe, Paul C ^a   Poste, George H ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; CATECHOL METHYLTRANSFERASE INHIBITOR; CILIARY NEUROTROPHIC FACTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LEVODOPA; PRAMIPEXOLE; ROPINIROLE; ROTIGOTINE; SELEGILINE; TOLCAPONE;

BRAIN DEPTH STIMULATION; BRAIN SURGERY; CELL TRANSPLANTATION; CLINICAL FEATURE; DYSKINESIA; FETUS CELL; GENE THERAPY; HEREDITY; NEUROTOXICITY; ON OFF PHENOMENON; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW;

EID: 0030989569     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(97)01050-X     Document Type: Review

References (114)

1. Parkinson, J. (1817) An Essay on the Shaking Palsy, Sherwood, Neely and Jones.
2. Braak H.et al. J. Neural Transm. 46:1995;15-31.
3. Forno, L. S. (1990) in Parkinson's Disease (Stern, G. M., ed.), pp. 185-239, Chapman and Hall Medical.
4. Agid, Y. et al. (1990) in Parkinson's Disease (Stern, G. M., ed.), pp. 99-126, Chapman and Hall Medical.
5. Morrish P. K., Sawle G. V., Brooks D. J. Mov. Disord. 11:1996;P547.
6. Hoehn M. M., Yahr M. D. Neurology. 17:1967;427-442.
7. Lees, A. J. (1990) in Parkinson's Disease (Stern, G. M., ed.), pp. 389-413, Chapman and Hall Medical.
8. Cotzias G. C., Van-Woert M. H., Schiffer L. M. New Engl. J. Med. 276:1967;374-379.
9. Barbeau A. Can. Med. Assoc. J. 101:1969;59-68.
10. Clarke C. E. Mov. Disord. 10:1995;250-256.
11. Sage J. I., Mark M. H. Neurology. 44(Suppl. 6):1994;S10-S14.
12. Marsden C. D., Parkes J. D. Lancet. i:1977;345-349.
13. Quinn N., Critchley P., Marsden C. D. Mov. Disord. 2:1987;73-91.
14. Cedarbaum J. M., Gandy S. E., McDowell F. H. Neurology. 41:1991;622-629.
15. Miller R., Chouinard G. Biol. Psychiatry. 34:1993;713-738.
16. Arts N., van De Vlasakker C., Tacke T., Horstink M. Lancet. 338:1991;1210-1211.
17. Boyce S., Rupniak N. M. J., Steventon M. J., Iversen S. D. Clin. Neuropharmacol. 13:1990;448-458.
18. Pearce R. K. B., Banerji T., Jenner P., Marsden C. D. Br. J. Pharmacol. 118(Suppl):1996;37P.
19. Jenner P. Mov. Disord. 11(Suppl. 1):1996;M8.
20. Lesser R. P.et al. Neurology. 29:1979;1253-1260.
21. Mizuno Y., Kondo T., Mori H. Neurology. 44(Suppl. 6):1994;S29-S34.
22. Bateman D. E. J. Neurol. Neurosurg. Psychiatry. 59:1995;555-565.
23. Bravi D.et al. Ann. Neurol. 36:1994;27-31.
24. Hammerstad, J. P., Woodward, W. R., Gliessman, P., Boucher, B. and Nutt, J. G. (1990) in The Basal Ganglia III (Bernardi, G., Carpenter, M. B., Di Chiara, G. and Morelli, M., eds), pp. 683-688, Plenum Press.
25. Jankovic J., Schwartz K., Vander-Linden C. Mov. Disord. 4:1989;303-309.
26. Montrasuc J. L., Rascol O., Senard J. M., Rascol A. J. Neurol. Neurosurg. Psychiatry. 57:1994;1034-1038.
27. Parkinson Study Group (1996) Ann. Neurol. 39, 37-45.
28. Birkmayer W.et al. J. Neural Transm. 64:1985;113-127.
29. Tetrud J. W., Langston J. W. Science. 245:1989;519-522.
30. Parkinson Study Group (1989) New Engl. J. Med. 321, 1364-1371.
31. Parkinson Study Group (1993) New Engl. J. Med. 328, 176-183.
32. Landau W. M. Neurology. 40:1990;1337-1339.
33. Parkinson Study Group (1991) Neurology 41, 771-773.
34. Mally J., Kovacs A. B., Stone T. W. J. Neurol. Sci. 134:1995;143-145.
35. Arnett C. D.et al. J. Neurochem. 49:1987;522-527.
36. Olanow C. W.et al. Ann. Neurol. 38:1995;771-777.
37. Lees A. J.et al. Br. Med. J. 307:1993;469-472.
38. Lees A. J.et al. Br. Med. J. 311:1995;1602-1607.
39. Olanow C. W., Kordower J. H., Freeman T. B. Trends Neurosci. 19:1996;102-109.
40. Gerlach M., Riederer P., Vogt H. Br. Med. J. 312:1996;704.
41. Lees A. J., Head J., Ben-Shlomo B. Br. Med. J. 312:1996;704.
42. Rabey J. M. J. Neural Transm. 45(Suppl.):1995;213-224.
43. Lieberman A. N., Goldstein M. Pharmacol. Rev. 37:1985;217-227.
44. Goetz G. G., Diederich N. J. Neurologic Clinics. 10:1992;527-540.
45. Pezzoli G., Canesi M., Pesenti A., Mariani C. B. J. Neural Transm. 45(Suppl.):1995;203-212.
46. Rinne U. K. Neurology. 39:1989;336-339.
47. Olanow C. W.et al. Mov. Disord. 9:1994;40-47.
48. Kapoor R.et al. Lancet. 333:1989;1445-1446.
49. Perez-Aharon J.et al. Neurology. 44(Suppl. 2):1994;A244.
50. Rascol O. Mov. Disord. 11(Suppl. 1):1996;P510.
51. Brunt E., Aitken C. J. Neurol. 243(Suppl. 2):1996;S38.
52. Del Dotto, P. et al. (1995) J. Neural Transm. 45, (Suppl.) 259-265.
53. Molho, E. S. et al. (1995) J. Neural Transm. 45, (Suppl.) 225-230.
54. Lees A. J., Shaw K. M., Stern G. M. Lancet. ii:1975;709-710.
55. Hely M.et al. J. Neurol. Neurosurg. Psychiatry. 57:1994;903-910.
56. Giovannini P.et al. Clin. Neuropharmacol. 11:1988;201-211.
57. Wright A., Lees A. J., Stern G. M. J. Neurol. Neurosurg. Psychiatry. 49:1986;482-484.
58. Hubble J. P.et al. Clin. Neuropharmacol. 18:1995;338-347.
59. Shannon, K. M. (1996) Mov. Disord. 11 (Suppl. 1), SS3.
60. Jori M. C.et al. Adv. Neurol. 53:1990;539-543.
61. Rinne U. K.et al. Mov. Disord. 11(Suppl. 1):1996;SS28.
62. Bottomley, J. M. and Sree Haran, N. (1990) in Basic, Clinical and Therapeutic Aspects of Alzheimer's and Parkinson's Diseases (Vol. 2) (Nagatsu, T., Fisher, A. and Yoshida, M., eds), pp. 581-584, Plenum Press.
63. Vidaihlet M. J.et al. Lancet. 336:1990;316-317.
64. Waddington, J. L. (1986) Trends Pharmacol. Sci. 223-224.
65. Goldstein, M., Leiberman, A. and Meller, E. (1985) Trends Pharmacol. Sci. 436-437.
66. Nakanishi T.et al. Eur. Neurol. 32(Suppl. 1):1992;9-22.
67. Eden R. J.et al. Pharmacol. Biochem. Behav. 38:1991;147-154.
68. Bedard P. J., Gomez-Mancilla B., Blanchette P., Cagnon C., Di Paola T. Can. J. Neurol. Sci. 19:1992;134-137.
69. Brooks D., Fuell D. J. Neurol. 243(Suppl. 2):1996;S9.
70. Grondin R., Blanchet P. D., Goulet M., Di Paolo T., Bedard P. J. Mov. Disord. 11(Suppl. 1):1996;P216.
71. Relja M. A.et al. Neurology. 46(Suppl. 2):1996;A475.
72. Waters C. H.et al. Neurology. 46(Suppl. 2):1996;A160.
73. Oertel W. H., Eichorn T. E., Becker M., Mai N. Neurology. 46(Suppl. 2):1996;A372.
74. Belluzzi J. D., Domino E. F., May J. M., Bankiewicz K. S., McAfee D. A. Mov. Disord. 9:1994;147-154.
75. Goetz C. G., Diederich N. J. Nat. Med. 2:1996;510-514.
76. Caparros-Lefebvre D.et al. J. Neurol. Neurosurg. Psychiatry. 56:1993;268-273.
77. Eden R. J., Wallduck M. S., Patel B., Owen D. A. A. Eur. J. Pharmacol. 175:1990;330-340.
78. Eden R. J.et al. Pharmacol. Biochem. Behav. 38:1991;147-154.
79. Bowen W. P., Coldwell M. C., Hicks F. R., Riley G. J., Fears R. Br. J. Pharmacol. 110(Suppl.):1993;93P.
80. Coldwell M. C., Hagan J., Middlemiss D., Tulloch I., Boyfield I. Br. J. Pharmacol. 119(Suppl.):1997;346P.
81. Pearce R. K. B., Banerji T., Jenner P., Marsden C. D. Br. J. Pharmacology. 118(Suppl.):1996;37P.
82. Parker S. G., Raval P., Yeulet S., Eden R. J. Eur.J. Pharmacol. 265:1994;17-26.
83. Mierau J. Clin. Neuropharmacol. 18(Suppl. 1):1995;S195-S206.
84. Mierau J.et al. Eur. J. Pharmacol. 290:1995;29-36.
85. Camacho-Ochoa M., Walker E. L., Evans D. L., Piercey M. F. Neurosci. Lett. 196:1995;97-100.
86. Mierau J., Schingnitz G. Eur. J. Pharmacol. 215:1992;161-170.
87. Rains C. P., Bryson H. M., Fitton A. Drugs. 49:1995;255-279.
88. Benedetti M. S.et al. Eur. J. Pharmacol. 187:1990;399-408.
89. Grondin R., Blanchet P. D., Goulet M., Di Paolo T., Bedard P. J. Mov. Disord. 11(Suppl. 1):1996;P216.
90. Grondin R., Goulet M., Di Paolo T., Bedard P. J. Brain Res. 735:1996;298-306.
91. Burton, K. and Calne, D. B. (1990) in Parkinson's Disease (Stern, G. M., ed.), pp. 269-294, Chapman and Hall Medical.
92. Kim M. H.et al. Neurology. 41(Suppl. 1):1991;122.
93. Manfredi M., Stocchi F., Vacca L. J. Neural Transm. (Suppl.). 45:1995;1-9.
94. De Michele, G. et al. (1996) in Advances in Neurology 69 (Battistin, L., Scarlato, G., Caraceni, T. and Ruggieri, S., eds), pp. 19-24, Lippincott-Raven Publishers.
95. Langston J. W., Ballard P., Tetrud J. W., Irwin I. Science. 219:1983;979-980.
96. Schapira A. H. V., Cooper J. M., Dexter D. J. Neurochem. 54:1990;823-827.
97. Zweig R. M., Singh A., Cardillo J. E., Langston J. W. Arch. Neurol. 49:1992;1205-1207.
98. Ikebe S., Tanaka M., Ozawa T. Mol. Brain Res. 28:1995;281-295.
99. Jenner P., Schapira A. H. V., Marsden C. D. Neurology. 42:1992;2241-2250.
100. Jenner P. Mov. Disord. 11(Suppl. 1):1996;M8.
101. Blunt S. B., Jenner P., Marsden C. D. Mov. Disord. 8:1993;129-133.
102. Mochizuki H., Goto K., Mori H., Mizuno Y. J. Neurol. Sci. 137:1996;120-123.
103. Walkinshaw G., Waters C. M. J. Clin. Invest. 95:1995;2458-2464.
104. Lang, A. E. (1992) in Handbook of Parkinson's Disease (2nd edn) (Koller, W. C., ed.), pp. 105-128, Marcel Dekker.
105. Marsden C. D. J. Neurol. Neurosurg. Psychiatry. 50:1987;105-106.
106. Johnson W. G., Hodge S. E., Duvoisin R. Mov. Disord. 5:1990;187-194.
107. Sawle G. V., Wroe S. J., Lees A. J., Brookes D. J., Frackowiak R. S. J. Ann. Neurol. 32:1992;609-617.
108. Lazzarini A. M.et al. Neurology. 44:1994;499-506.
109. Golbe L. I., Di Iorio G., Bonavita V., Miller D. G., Duvoisin R. C. Ann. Neurol. 27:1990;276-282.
110. Polymeropoulos M. H.et al. Science. 274:1996;1197-1199.
111. Gasser T.et al. Mov. Disord. 8:1993;408.
112. Nanko S.et al. Am. J. Med. Genet. 54:1994;361-364.
113. Kurth J. H., Kurth M. C., Poduslo S. E., Schwankhaus J. D. Ann. Neurol. 33:1993;368-372.
114. Nanko S., Ueki A., Hattori M. Neurosci. Lett. 204:1996;125-127.